Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.50
+0.07 (+0.40%)
Official Closing Price
Updated: 4:10 PM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
June 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services
June 08, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims
May 25, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
May 23, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
May 17, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting
May 12, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure
May 10, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports First Quarter 2022 Financial Results
May 03, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
May 02, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM
April 19, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss First Quarter 2022 Financial Results at 8 a.m. ET on May 3, 2022
April 04, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at 2022 American Academy of Neurology Annual Meeting
April 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
March 30, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
March 21, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...
Via
FinancialNewsMedia
Exposures
COVID-19
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
February 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
February 07, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Research Finds COVID Pandemic Worsened Health Equity Gap
February 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
January 18, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Statement Following New York Jury Ruling in Opioids Trial
December 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
December 22, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
December 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
November 10, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
The $11 Trillion Healthcare Industry Is About To Change Forever
November 04, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government...
Via
FinancialNewsMedia
Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets
November 03, 2021
From
Teva Pharmaceutical Industries Ltd.
Via
Business Wire
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
November 02, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
November 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.